Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Foghorn Therapeutics (FHTX) Other Non-Current Liabilities (2021 - 2025)

Historic Other Non-Current Liabilities for Foghorn Therapeutics (FHTX) over the last 3 years, with Q3 2025 value amounting to $656000.0.

  • Foghorn Therapeutics' Other Non-Current Liabilities changed N/A to $656000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $656000.0, marking a year-over-year change of. This contributed to the annual value of $29000.0 for FY2022, which is 7972.03% down from last year.
  • As of Q3 2025, Foghorn Therapeutics' Other Non-Current Liabilities stood at $656000.0.
  • Foghorn Therapeutics' 5-year Other Non-Current Liabilities high stood at $856000.0 for Q1 2025, and its period low was $29000.0 during Q4 2022.
  • For the 3-year period, Foghorn Therapeutics' Other Non-Current Liabilities averaged around $319333.3, with its median value being $143000.0 (2021).
  • Over the last 5 years, Foghorn Therapeutics' Other Non-Current Liabilities had its largest YoY gain of 6608.19% in 2022, and its largest YoY loss of 7972.03% in 2022.
  • Quarter analysis of 3 years shows Foghorn Therapeutics' Other Non-Current Liabilities stood at $143000.0 in 2021, then tumbled by 79.72% to $29000.0 in 2022, then skyrocketed by 2162.07% to $656000.0 in 2025.
  • Its Other Non-Current Liabilities was $656000.0 in Q3 2025, compared to $757000.0 in Q2 2025 and $856000.0 in Q1 2025.